Capricor Therapeutics, Inc. (CAPR) — Financial statements
Income statement, balance sheet, and cash flow for Capricor Therapeutics, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00↓100.0% | 22↓11.5% | 25↑886.8% | 3↑941.8% | 0.24 | |
| Cost of Revenue | 0.00↓100.0% | 50↑37.1% | 36↑67.1% | 22 | 0.00 | |
| Gross Profit | 0.00↑100.0% | -28↓145.8% | -11↑41.5% | -19↓7966.7% | 0.24 | |
| Operating Expenses | ||||||
| R&D Expenses | 84↑69.0% | 50↑37.1% | 36↑67.1% | 22↑60.8% | 14 | |
| General & Administrative Expenses | 0.00↓100.0% | 15↑16.1% | 13↑22.8% | 10↑37.0% | 8 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 24↑59.3% | 15↑16.1% | 13↑22.8% | 10↑37.0% | 8 | |
| Other Expenses | 0.00↑100.0% | -50↓37.1% | -36↓67.1% | -22 | 0.00 | |
| Operating Expenses | 108↑627.4% | 15↑16.1% | 13↑22.8% | 10↓50.8% | 21 | |
| Total Costs & Expenses | 108↑66.8% | 65↑31.6% | 49↑52.7% | 32↑52.2% | 21 | |
| Operating Results | ||||||
| Operating Income | -108↓154.1% | -43↓76.8% | -24↑18.9% | -30↓41.8% | -21 | |
| Depreciation & Amortization | 0.00↓100.0% | 1↑33.3% | 1↑100.5% | 0.53↑117.0% | 0.25 | |
| EBITDA | -108↓162.9% | -41↓78.8% | -23↑21.1% | -29↓40.9% | -21 | |
| EBIT | -108↓154.1% | -43↓76.8% | -24↑18.9% | -30↓41.8% | -21 | |
| Interest & Other Income | ||||||
| Net Interest Income | 3↑45.8% | 2↑27.4% | 2↑231.5% | 0.52 | 0.00 | |
| Interest Income | 6↑184.1% | 2↑27.4% | 2↑231.5% | 0.52 | 0.00 | |
| Interest Expense | 3 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Non-Operating Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Other Income / Expenses | 3↑47.7% | 2↑17.2% | 2↑164.1% | 0.68↓26.0% | 0.92 | |
| Income Before Tax | -105↓159.6% | -40↓81.6% | -22↑23.2% | -29↓44.9% | -20 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -105↓159.6% | -40↓81.6% | -22↑23.2% | -29↓44.9% | -20 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -105↓159.6% | -40↓81.6% | -22↑23.2% | -29↓44.9% | -20 | |
| Bottom-Line Net Income | -105↓159.6% | -40↓81.6% | -22↑23.2% | -29↓44.9% | -20 | |
| EPS (Basic) | -2.26↓96.5% | -1.15↓38.6% | -0.83↑29.7% | -1.18↓35.6% | -0.87 | |
| EPS (Diluted) | -2.26↓96.5% | -1.15↓38.6% | -0.83↑29.7% | -1.18↓35.6% | -0.87 | |
| Weighted Average Shares | 46↑32.0% | 35↑31.5% | 27↑9.1% | 25↑6.3% | 23 | |
| Weighted Average Diluted Shares | 46↑32.0% | 35↑31.5% | 27↑9.1% | 25↑6.3% | 23 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.